People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.2M | 2018 |
Teofilo Raad at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Teofilo Raad on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Michael Higgins | 1 | 9 |
| SCOTT ROCKLAGE | 1 | 9 |
| Terrance McGuire | 1 | 9 |
| Robert Clarke | 1 | 7 |
| Amit Munshi | 1 | 5 |
| Kurt Graves | 1 | 5 |
| MICHAEL J. HIGGINS | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| Sameer Harish | 1 | 3 |
| Hojabr Alimi | 1 | 3 |
| Matthew Sherman | 1 | 3 |
| William Duke | 1 | 2 |
| Richard Conley | 1 | 2 |
| JAMES ROACH | 1 | 2 |
| David Maki | 1 | 2 |
| David Hava | 1 | 2 |
| Richard D. Batycky | 1 | 1 |
| Christopher D. Cabell | 1 | 1 |
| Gregory French | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.